EP1570054A2 - Trans-sialidases issues de trypanosoma congolense - Google Patents

Trans-sialidases issues de trypanosoma congolense

Info

Publication number
EP1570054A2
EP1570054A2 EP03785794A EP03785794A EP1570054A2 EP 1570054 A2 EP1570054 A2 EP 1570054A2 EP 03785794 A EP03785794 A EP 03785794A EP 03785794 A EP03785794 A EP 03785794A EP 1570054 A2 EP1570054 A2 EP 1570054A2
Authority
EP
European Patent Office
Prior art keywords
trans
sialidase
nucleic acid
enzymes
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP03785794A
Other languages
German (de)
English (en)
Inventor
Joachim Schmitt
Günter Boehm
Bernd Stahl
Roland Schauer
Evelin c/o Dr. Wolfgang Raudies TIRALONGO
Silke Schrader
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nutricia NV
Original Assignee
Nutricia NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nutricia NV filed Critical Nutricia NV
Publication of EP1570054A2 publication Critical patent/EP1570054A2/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1048—Glycosyltransferases (2.4)
    • C12N9/1081—Glycosyltransferases (2.4) transferring other glycosyl groups (2.4.99)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Definitions

  • the invention relates to novel enzymes which transfer sialic acids from a donor molecule (e.g. oligosaccharides, polysialic acids, glycosylated proteins, glycosylated peptides, glycosylated lipids (e.g. gangliosides) and other glycosylated low and high molecular weight molecules) to an acceptor molecule (e.g. oligo - and polysaccharides, glycosylated proteins, glycosylated peptides, glycosylated lipids and other glycosylated low and high molecular weight molecules) are transmitted (trans-sialidases).
  • the enzymes were isolated from the unicellular Trypanosoma congolense.
  • the invention further relates to functional equivalents of these enzymes; the nucleic acid sequences coding for these enzymes and their functional equivalents; Expression constructs and vectors containing these sequences; recombinant microorganisms which carry a coding nucleic acid sequence according to the invention; Process for the recombinant production of enzymes according to the invention; Process for isolating enzymes according to the invention from Trypanosoma congolense; Process for the enzymatic sialization of acceptor molecules using enzymes according to the invention; Effectors of the trans-sialidases according to the invention; the use of nucleic acid sequences, enzymes, effectors or sialyzation products according to the invention for the production of vaccines, medicines, food or nutritional supplements; as well as the agents produced according to the invention itself.
  • Trans-sialidases can transfer sialic acids, preferably alpha-2,3-linked sialic acids, from a donor molecule to an acceptor molecule, again forming alpha-2,3-glycosidic bonds, preferably at a ⁇ -terminal galactose residue.
  • Neuraminic acid (5-amino-3,5-dideoxy-D-glycero-D-galacto-nonulo-pyranosonic acid) is an amino sugar with a backbone made of nine carbon atoms, which is linked to one by the carboxyl group on carbon atom 2 receives a strongly acidic pK value of 2.2 and is therefore negatively charged under physiological conditions.
  • the unsubstituted form is very unstable and does not occur in free form in nature (Schauer, 1982). However, more than 40 natural derivatives of neuraminic acid are now known (Schauer and Kamerling, 1997).
  • N-acetylneuraminic acid (Neu ⁇ Ac), the precursor of all glycosidically bound sialic acids (Schauer, 1991) and -Glycolylneuraminic acid (Neu ⁇ Gc), which are obtained by hydroxylation of the methyl group of the ⁇ / -acetyl residue of CMP-Neu5Ac emerges (Shaw and Schauer, 1988).
  • the hydroxyl groups of these two sialic acids can be substituted by acetyl, lactyl, methyl, sulfate and phosphate residues in different combinations, which leads to the great structural diversity of sialic acids (Schauer, 1991; Schauer and Kamerling, 1997).
  • sialic acids are bound as a component of oligosaccharides, polysaccharides and in particular
  • sialic acids protect glycoproteins and cells from attack
  • sialic acid-containing mucous membranes of the gastrointestinal tract not only provide effective protection against the digestive enzymes, but also protect the underlying tissue against the penetration of pathogenic bacteria (Keim and Schauer, 1997).
  • Sialic acids play a very important role in molecular and cellular recognition processes. They mask receptors and thus prevent interactions between receptors and ligands (Schauer, 1985; Keim and Schauer, 1997). So protect sialic acids e.g. B. serum glycoproteins and erythrocytes prior to degradation and phagocytosis by masking underlying galactose residues. If the terminal sialic acids are split off, the subterminal galactose residues can be bound by lectins on hepatocytes or phagocytes and endocytosis of the serum proteins or erythrocytes occurs. Another example is the protection of the body's own tissues, but also many highly sialylated tumors, before they are recognized by the immune system (Pilatte et al., 1993). If the protective sialic acid layer is lost, autoimmune reactions can occur.
  • Sialic acids also serve as recognition sites for the body's own cells and hormones and thus play an important role in cellular interactions (Keim and Schauer, 1997).
  • endothelial cells express selectins on their surface that recognize certain sialylated structures (e.g. sialyl-Lewis X) on leukocytes so that they can bind to the endothelial cells and penetrate into the tissue (Lasky, 1995).
  • the activation of the T cells of the humoral immune defense is influenced by the action of trans-sialidases (Gao et al., 2001).
  • Sialoadhesins such as myelin-associated glycoprotein (MAG) also bind to sialylated glycans in a highly specific manner (Keim et al., 1996; Crocker et al., 1998).
  • the myelin-associated glycoprotein is involved in the nervous system, among other things, in myelination and in the regulation of axonal growth. It is therefore not surprising that it has recently been found that trans-sialidases are involved in the differentiation of nerve cells and glial cells through the transfer of sialic acids (Chuenkova et al., 2001).
  • CD-22 is another sialic acid binding receptor that occurs on lymphocytes and enables the "conversation" of T and B lymphocytes.
  • the Siglecs family now consists of more than 10 representatives characterized by molecular biology.
  • sialic acids are not only important in the body's own recognition processes, they are also receptors for some bacteria, viruses and toxins.
  • B. the binding of the tetanus toxin to gangliosides of ne ⁇ tensynapses via sialic acids (Schauer et al., 1995).
  • Sialic acid-specific adhesion via microbial lectins (Sharon and üs, 1997) is often a critical step in infectious diseases, such as that caused by some E. co / i strains Newborn meningitis or gastric mucosal infections caused by Helicobacter pylo ⁇ .
  • Influenza A and B viruses in particular, dock onto the cells to be infected via sialic acid (Schauer, 2000).
  • Sialic acids are essential modulators of the biological behavior of tumors (Schauer, 2000).
  • Figure 1 shows a comparison of the partial amino acid sequences of the trans-sialidases TS1 and TS2 according to the invention. Identical amino acids in both sequences are marked in dark. The agreement (identity) of the two partial sequences is only about 50%.
  • Figure 2 shows the different reaction modes of sialidase, sialyltransferases and trans-sialidases
  • Figure 3 shows a comparison of the amino acid sequence of the sialidase from Trypanosoma rangeli (T. r. S), the trans-sialidase from Trypanosoma cruzi (T. er. TS) and the trans-sialidase from Trypanosoma brucei brucei (T. b. Br. TS) with partial sequences of the two trans-sialidases according to the invention from Trypanosoma congolense (T. con. TS1 and T. con. TS2).
  • Amino acids that are identical in all sequences are shown in white on a dark gray background.
  • Amino acids that are identical in at least 4 of the 5 sequences are printed in black on dark gray, while amino acids that match in at least 3 of the 5 sequences are highlighted with a lighter gray.
  • the object of the present invention was to provide novel means by means of which sialic acid-controlled biological or patho-biological processes can be influenced.
  • the above task was surprisingly achieved by providing novel enzymes with trans-sialidase activity and the coding sequences thereof from Trypanosoma congolense.
  • a first object of the invention relates to polynucleotides which code for proteins with trans-sialidase activity and can be isolated from Trypanosoma congolense, these proteins preferably catalyzing the transfer of sialic acid from a donor to an acceptor molecule.
  • Preferred polynucleotides comprise at least one nucleic acid sequence according to SEQ ID NO: 1 or 3, or represent fragments thereof, which comprise at least 15 contiguous nucleotide residues.
  • the invention also relates to the complementary polynucleotides and fragments; and the nucleotide sequences derived from these polynucleotides by degenerating the genetic code.
  • the invention further relates to oligonucleotides which hybridize with a polynucleotide according to the invention, in particular under stringent conditions.
  • the invention also relates to polynucleotides which contain an oligonucleotide as defined above, in particular under stringent ones Conditions, hybridize and code for a gene product from microorganisms of the genus Trypanosoma.
  • the invention also relates to polypeptides which are encoded by a polynucleotide which comprises a nucleic acid sequence as defined above; or which have an amino acid sequence which comprises at least 10 contiguous amino acids according to SEQ ID NO: 2 or 4; as well as functional equivalents of which have trans-sialidase activity.
  • the invention relates in particular to trans-sialidases or functional equivalents thereof with trans-sialidase activity, characterized by one of the following partial amino acid sequences:
  • TDTVAKYSTDGGRTWKREVIIPNGR (items 1 to 25 according to SEQ ID NO: 2)
  • FRIPSLVEIDGVLIATFDTRYLRASDSSLI (items 1 to 30 according to SEQ ID NO: 4).
  • a preferred trans-sialidase 1 is characterized by at least one of the following characteristics:
  • TS2 trans-sialidase 2
  • polynucleotides and polypeptides according to the invention described above in particular coding nucleic acid sequences and amino acid sequences, can be derived from the organism Trypanosoma congolense. However, they are also accessible using synthetic, in particular chemical, biochemical, enzymatic, genetic engineering and transgenic methods.
  • the invention further relates to functional equivalents of trans-sialidases according to the invention.
  • the invention furthermore relates to expression cassettes comprising, in operative linkage with at least one regulatory nucleic acid sequence, a nucleic acid sequence as defined above. Furthermore, the invention also includes recombinant vectors containing at least one of these expression cassettes.
  • the invention also relates to prokaryotic or eukaryotic hosts transformed with at least one vector as defined above.
  • the invention further relates to the use of an expression cassette, a vector or a host as defined above for the recombinant production of a protein with trans-sialidase activity.
  • the invention also relates to a method for the enzymatic sialization of an acceptor molecule, characterized in that the acceptor molecule is incubated with a donor containing sialic acid residues in the presence of a trans-sialidase as defined above and the sialylated acceptor is isolated.
  • Such processes are characterized by at least one further of the following properties: a) the donor is selected from sialic acids bound to oligosaccharides, polysaccharides, polysialic acids, glycoproteins and glycolipids, such as in particular lactoferrins, glycolized whey proteins and caseins and fragments thereof; b) the acceptor is selected from ß-galactose-containing polymers, such as ß-galactooligosaccharides, lactitol, lactobionic acid, methyl-ß-lactoside, acetyllactosamines, galactopyranosides, trans-galactooligosaccharides, polygalactose and other glycoconjugates (end-bonded) or ugly bound ß (1-4) -galactose; or galactose.
  • ß-galactose-containing polymers such as ß-galactooligosaccharides, lactitol, lactobionic
  • Another aspect of the present invention relates to the use of a trans-sialidase according to the invention, a nucleic acid sequence coding therefor, or a sialization product produced according to the invention for the manufacture of a medicament, food or food supplement or a food additive for the prevention or treatment of sialic acid-controlled parasitic, bacterial or viral infections; for the treatment of tumor diseases; to treat diseases associated with a developmental disorder of the tissue; for the treatment of diseases of the immune system; for the treatment of autoimmune reactions; for the treatment of diseases with impaired cell communication; and / or to treat inflammation.
  • the invention relates to the use of a trans-sialidase according to the invention as defined above, for the development of a trypanosomiasis vaccine or for the development of enzyme inhibitors for the treatment or prevention of trypanosoma infections.
  • the invention further relates to the use of a trans-sialidase, a nucleic acid sequence coding therefor or a sialylated product produced according to the invention for the manufacture of a medicament, nutritional supplement or food for protecting the body's own cells or tissues or glycoproteins from enzymatic action.
  • the invention furthermore relates to the use of a trans-sialidase, a nucleic acid sequence coding therefor or a sialylated product produced according to the invention for the manufacture of a medicament,
  • Dietary supplement or food for influencing the development and / or morphogenesis of body tissues Dietary supplement or food for influencing the development and / or morphogenesis of body tissues.
  • the invention further relates to effectors of the trans-sialidase activity of a trans-sialidase, selected from a) polypeptide ligands which interact with a trans-sialidase as defined above; b) low molecular weight effectors which modulate the biological activity of a trans-sialidase as defined above; and c) antisense nucleic acid sequences to form a nucleic acid sequence as defined above.
  • the invention relates to the use of such an effector for the manufacture of a medicament, dietary supplement or food for the treatment or prevention of diseases associated with trans-sialidase activity.
  • the invention further relates to a process for isolating an enzyme with trans-sialidase activity, wherein a) Trypanosoma congolense is cultivated in a medium, and b) the desired product from the culture supernatant is obtained by ion exchange chromatography using a salt gradient, optionally followed by isoelectric focusing , Gel filtration, affinity chromatography and / or protein precipitation, isolated.
  • the invention relates to pharmaceutical or gene therapy agents containing in a pharmaceutically or gene therapy-compatible carrier at least one effector as defined above
  • the significance of the present invention results from the influence of the sialic acid-controlled parasitic, bacterial and viral infection mechanisms which is now possible with this invention, the influence on cell communication and the immune system and the change in the regulation and development mechanisms of human and animal tissue and of tumors. This is achieved by the targeted transfer of sialic acids to biologically relevant glycostructures (glycans, glycan derivatives and glycoconjugates) using the trans-sialidases described here.
  • sialic acids results, for example, in products for changing inflammatory reactions, changing cellular interactions in the human and animal body, protecting the body's own tissues against attacks by the patient's own immune system (autoimmune reactions), and "unmasking" cancer cells in a patient's body so that they to be fought again by the body's immune system (cancer therapy and cancer prevention), combating the penetration of pathogenic bacteria into the human and animal body, preventing and combating viral infections, combating gastric mucosal infections by Helicobacter py / ori, combating newborn meningitis caused by bacteria and viruses, preventive and therapeutic influence of Receptors of eukaryotic and prokaryotic pathogenic organisms, bacteria, viruses and toxins to prevent their development in the human and animal body, inhibition of the binding of cholera toxin to human and animal mucous membranes of the digestive tract, development of a vaccine against trypanosomiasis, development of enzyme inhibitors to combat ( Therapy) of Trypanosoma infections, influencing molecular
  • trans-sialidases according to the invention are characterized by the following partial DNA and amino acid sequences as well as by other DNA sequence homologues, e.g. characterized with a more than 60 percent agreement (identity) to these partial sequences.
  • Partial amino acid sequence of the enzyme TS1 (SEQ ID NO: 2): TDTVAKYSTDGGRTWKREVIIPNGRVDAHYSRWDPTWAKGNNIYVLVGRYNVTR GYWHNRNNKAGIADWEPFVYKGTVNVGTKGNATDVSISWERTALKSLYNFPVSGS PGTQFLGGAGGGWTSNGTIVLPVQARNKANRWSMILYSADDGKSWHFGKGEA GVGTSEAALTEWDGKLLISARSDGGQGYRMIFESSDLGATWKEMLNSISRVIGNSP GRSGPGSSSGFITVTVEGVPVMLITHPKNLKGSYYRDRLQLWMTDGNRMWHVGQ VSEGDDNSAYSSLLYTPDGVLYCLHEQNIDEVYSLHLVRLVDELKSIKSTALVWKAQ DELLLGNCLPGDKYDPGCDGIPTAGLAGLLVGPLTEKTWPDAYRCVNAATSGAVST AEGVRLDVGGGGHWWPVSEQGQDQ
  • DNA subsequence of the enzyme TS2 (SEQ ID NO: 3): ⁇ 'TTCCGAATTCCCTCACTTGTTGAGATAGACGGCGTGCTTATCGCGACATTCGA TACACGTTATCTTCGCGCTTCCGACAGCAGTCTCATAGACACAGCTATGAAATA CAGTGCCGATCAGGGGAAGACGTGGAAAACTGAAATCATAATAAAAAATGCTAG ACTAACTGATAACTTTTCCCGCGTCGTTGATCCAACGGTTGTTGTTAAGGGTGA TAACTTGTTTATTTTTGTTGGGAGGTACAACACCTCATCTGCCCCATGGGTCTG GCAGGAAAACGGTAAAGACTGGGATGTACTGTTGTACAAGGCCAAGGTGAGGA AGGAATCAGCGGGTGGGGTACCATCAGTGAGCTTTACATGGGACGAACCCCTA TACCTGAAGCATCTGCTCACCTCTGTCGGTAAAATAGACGGCAGGTCCCTCATA CAATACATTGGTGGCGTTGGAAATGGTATTGTAACACCGA
  • Table 1 Basic data of the two trans-sialidases TS1 and TS2
  • the two substances claimed here are two enzymes that transfer sialic acids from a donor molecule to an acceptor molecule.
  • Both enzymes act as donors to glycans, e.g. B. to oligosaccharides, polysaccharides, polysialic acids, glycoproteins and glycolipids, bound sialic acids.
  • the glycoproteins include lactoferrins (from humans, cows, goats, sheep, horses, camels and other animals), glycolized whey proteins (from humans, cows, goats, sheep, horses, camels and other animals) and caseins (from humans, cows) , Goat, sheep, horse, camel and other animals) as well as other glycolized proteins of human, animal and vegetable origin as well as parts thereof, e.g. B.
  • Both trans-sialidases have a good acceptor specificity for galactooligosaccharides, in particular for beta-galacto-oligosaccharides, such as e.g. B. Vivinal GOS from Borculo Domo Ingredients (BDI) and Oligomate 55 from Yak ⁇ lt.
  • lactitol, lactobionic acid, methyl- ⁇ -lactoside, acetyllactosamine, galactopyranoside, trans-galactooligosaccharide, polygalactose and other glycoconjugates with terminally bound ⁇ (1-3) or ⁇ (1-4) galactose can act as acceptors.
  • Methylation of the galactose residue leads to a decrease in the acceptor function.
  • the methylation of a glucose residue (e.g. in the case of lactose) has little influence on the Acceptor.
  • the monosaccharide galactose also serves as an acceptor, albeit with less specificity.
  • the TS1 enzyme shows an approximately twice as efficient transfer of the sialic acids to the corresponding acceptors as the TS2 enzyme.
  • the substrates can be free, i.e. soluble or cell membrane bound.
  • alpha-2,3-linked terminal sialic acids to beta-1,4-linked terminal galactose residues is also from the trans-sialidases of Typanosoma cruzi (Schenkman et al., 1991; Vandekerckhove et al., 1992; Scudder et al ., 1993) and Trypanosoma brucei (Engstier et al., 1992, 1993, 1995).
  • TSI and TS2 differ from the already known enzymes.
  • TS1 and TS2 are thus clearly characterized as new substances (trans-sialidases). See the next paragraph for further delimitation.
  • trans-sialidase was first described in the American trypanosome species Trypanosoma cruz (Schenkmann et al., 1991). A little later, the enzyme was also detected in the African species Trypanosoma brucei gambiense, Trypanosoma brucei rhodesiense and Trypanosoma brucei brucei (Engstier et al., 1993, Pontes de Carvalho et al., 1993, Engstier et al., 1995).
  • trans-sialidase was found in endotrypanum species (parasites that attack the sloth) (Medina-Acosta et al., 1994 ), in Corynebacterium diphtheriae (Mattos-Guaraldi et al., 1998) and in human plasma (Tertov et al. 2001), so-called sialidases were known long before the detection of trans-sialidases, which are glycohydrolases, the sialic acids of transfer a donor molecule exclusively to water, which means that the sialic acids hydrolyze from oligosaccharides and glycoconjugates.
  • CMP cytidine monophosphate
  • the trans-sialidases claimed here do not only transfer sialic acids from a donor molecule to water, as do pure sialidases. However, if a suitable acceptor is missing, the trans-sialidases claimed here hydrolyze the sialic acids as well as the simple sialidases. The trans-sialidases claimed here also do not require activated sialic acids for their transfer reaction like the previously mentioned sialyltransferases. The trans-sialidases also have a broader donor and acceptor specificity than the sialyltransferases and are therefore particularly versatile. The trans-sialidases claimed here are therefore more advantageous for industrial use than the pure sialidases and sialyltransferases.
  • the enzyme TS1 claimed here has an agreement (identity) of less than 60% for the corresponding partial amino acid sequence of the trans-sialidase from Trypanosoma brucei brucei and an agreement of less than 50% for the corresponding partial sequence of Trypanosoma cruzi.
  • the enzyme TS2 claimed here has an agreement (identity) of less than 50% for the corresponding partial amino acid sequence of the trans-sialidase from Trypanosoma brucei brucei and an agreement of less than 50% for the corresponding partial sequence of Trypanosoma cruzi (see Figure 3). Furthermore, it is known that the amino acid correspondence between the trans-sialidases of trypanosomes and the known sialidases and trans-sialidases of bacteria and viruses is only 20% to 30% (Chuenkova et al., 1999, Montagna et al., 2002 ).
  • enzymes described here are thus newly characterized substances (enzymes), whose agreement (identity) with the corresponding DNA and amino acid sequences of other known enzymes of similar function are below 60%.
  • Polypeptides in the sense of the invention comprise characteristic partial fragments of the amino acid sequences according to the invention, as well as amino acid sequences of the enzymes according to the invention and the functional equivalents thereof.
  • “Functional equivalents” or analogs of the specifically disclosed polypeptides are, within the scope of the present invention, different polypeptides which furthermore have the desired biological activity as defined above (such as substrate specificity).
  • “functional equivalents” are understood to mean, in particular, mutants which, in at least one of the sequence positions mentioned above, have a different amino acid than the one specifically mentioned, but nevertheless have one of the biological activities mentioned here.
  • “Functional equivalents” thus include the mutants obtainable by one or more amino acid additions, substituents, deletions and / or inversions, the changes mentioned being able to occur in any sequence position as long as they lead to a mutant with the property profile according to the invention.
  • Functional equivalence is particularly given when the reactivity patterns between mutant and unchanged polypeptide match qualitatively, ie, for example, the same substrates are implemented at different speeds.
  • Salts means both salts of carboxyl groups and acid addition salts of amino groups of the protein molecules according to the invention.
  • Salts of carboxyl groups can be prepared in a manner known per se and include inorganic salts, such as, for example, sodium, calcium, ammonium, iron and zinc salts, and salts with organic bases, such as, for example, amines, such as triethanolamine, arginine, lysine , Piperidine and the like.
  • Acid addition salts such as, for example, salts with mineral acids, such as hydrochloric acid or sulfuric acid, and salts with organic acids, such as acetic acid and oxalic acid, are also a subject of the invention.
  • “Functional derivatives” of polypeptides according to the invention can also be prepared on functional amino acid side groups or on their N- or C-terminal end using known techniques.
  • Such derivatives include, for example, aliphatic esters of carboxylic acid groups, amides of carboxylic acid groups, obtainable by reaction with ammonia or with a primary or secondary amine; N-acyl derivatives of free amino groups, produced by reaction with acyl groups; or O-acyl derivatives of free hydroxyl groups, produced by reaction with acyl groups.
  • “Functional equivalents” naturally also include polypeptides that are accessible from other organisms as well as naturally occurring variants. For example, regions of homologous sequence regions can be determined by sequence comparison and, based on the specific requirements of the invention, equivalent enzymes can be determined.
  • “Functional equivalents” also include fragments, preferably individual domains or sequence motifs, of the polypeptides according to the invention which, for example, have the desired biological function.
  • “Functional equivalents” are also fusion proteins which have one of the abovementioned polypeptide sequences or functional equivalents derived therefrom and at least one further, functionally different, heterologous sequence in functional N- or C-terminal linkage (ie without mutual substantial functional impairment of the fusion protein parts)
  • Non-limiting examples of such heterologous sequences are, for example, signal peptides, enzymes, immunoglobulins, surface antigens, receptors or receptor ligands.
  • “Functional equivalents” of trans-sialidases according to the invention are in particular enzymes whose amino acid sequences or partial sequences to the corresponding amino acid sequence or partial sequence according to SEQ ID NO: 2 or 4 have a sequence identity (sequence homology) of at least 60%, in particular at least 65% or at least 70%, such as e.g. 75%, 80%, 85%, 90%, 95%, 98% or 99%, calculated according to the algorithm of Pearson and Lipman, Proc. Natl. Acad, Sei. (USA) 85 (8), 1988, 2444 -2448.
  • equivalents according to the invention include proteins of the above-mentioned type in deglycosy healer or glycosylated form and also modified forms obtainable by changing the glycosylation pattern.
  • homologs of the proteins or polypeptides of the invention can be generated by mutagenesis, e.g. by point mutation, lengthening or shortening of the protein.
  • the term "homolog” as used herein also refers to a variant form of the protein that acts as an agonist or antagonist of protein activity.
  • Homologs of the proteins according to the invention can be identified by screening combinatorial banks of mutants, such as, for example, shortening mutants.
  • a varied bank of protein variants can be generated by combinatorial mutagenesis at the nucleic acid level, such as, for example, by enzymatic ligation of a mixture of synthetic oligonucleotides. It are a variety of methods that can be used to generate banks of potential homologs from a degenerate oligonucleotide sequence. Chemical synthesis of a degenerate gene sequence can be performed in an automated DNA synthesizer, and the synthetic gene can then be ligated into an appropriate expression vector.
  • degenerate set of genes makes it possible to provide all the sequences in a mixture which encode the desired set of potential protein sequences.
  • Methods for the synthesis of degenerate oligonucleotides are known to the person skilled in the art (eg Narang, SA (1983) Tetrahedron 39: 3; Itakura et al. (1984) Annu. Rev. Biochem. 53: 323; Itakura et al., (1984) Science 198: 1056; Ike et al. (1983) Nucleic Acids Res. 11: 477).
  • Polynucleotides in the sense of the present invention comprise characteristic partial fragments of the nucleic acid sequences according to the invention which code for partial amino acid sequences of enzymes according to the invention, as well as nucleic acid sequences which code for enzymes and their functional equivalents. Polynucleotides preferably comprise more than about 20, in particular more than about 30, for example more than about 45 or more than about 60 nucleic acid residues.
  • Oligonucleotides in particular comprise a sequence of less than about 60, preferably less than about 45, in particular less than about 30 or less than about 20 nucleic acid residues.
  • nucleic acid sequences are, in a manner known per se, by chemical synthesis from the nucleotide building blocks, such as, for example, by fragment condensation of individual overlapping, complementary ones
  • Nucleic acid building blocks of the double helix can be produced.
  • the chemical synthesis of oligonucleotides can be carried out, for example, in a known manner using the phosphoamidite method (Voet, Voet, 2nd edition, Wiley Press New York, pages 896-897).
  • the attachment of synthetic oligonucleotides and filling of Gaps using the Klenow fragment of DNA polymerase and ligation reactions as well as general cloning methods are described in Sambrook et al. (1989) Molecular Cloning: A laboratory manual, Cold Spring Harbor Laboratory Press.
  • the invention also relates to nucleic acid sequences (single and double-stranded DNA and RNA sequences, such as cDNA and mRNA) coding for one of the above polypeptides and their functional equivalents, which e.g. are also accessible using artificial nucleotide analogs.
  • the invention relates both to isolated nucleic acid molecules which code for polypeptides or proteins or biologically active sections thereof, and to nucleic acid fragments which e.g. can be used for use as hybridization probes or primers for identifying or amplifying coding nucleic acids according to the invention.
  • nucleic acid molecules according to the invention can also contain untranslated sequences from the 3 'and / or 5' end of the coding gene region
  • nucleic acid molecule is separated from other nucleic acid molecules that are present in the natural source of the nucleic acid and, moreover, can be substantially free of other cellular material or culture medium when produced by recombinant techniques, or free of chemical precursors or other chemicals be when it's chemically synthesized.
  • a nucleic acid molecule according to the invention can be isolated using standard molecular biological techniques and the sequence information provided according to the invention.
  • cDNA can be isolated from a suitable cDNA library by using one of the specifically disclosed complete sequences or a portion thereof as a hybridization probe and standard hybridization techniques (as described, for example, in Sambrook, J., Fritsch, EF and Maniatis, T. Molecular Cloning: A Laboratory Manual. 2nd ed., Cold Spring Harbor Laboratory, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, 1989).
  • a nucleic acid molecule comprising one of the disclosed sequences or a portion thereof can be isolated by polymerase chain reaction using the oligonucleotide primers which have been created on the basis of this sequence.
  • the nucleic acid amplified in this way can be cloned into a suitable vector and characterized by DNA sequence analysis.
  • the oligonucleotides according to the invention can also be produced by standard synthesis methods, for example using an automatic DNA synthesizer.
  • the invention further comprises the nucleic acid molecules "complementary" to the specifically described nucleotide sequences or a section thereof.
  • the nucleotide sequences according to the invention enable the generation of probes and primers which can be used for the identification and / or cloning of homologous sequences in other cell types and organisms.
  • probes or primers usually comprise a nucleotide sequence region which, under stringent conditions, can be attached to at least about 12, preferably at least about 25, e.g. about 40, 50 or 75 successive nucleotides of a sense strand of a nucleic acid sequence according to the invention or a corresponding antisense strand are hybridized.
  • nucleic acid sequences according to the invention are derived from SEQ ID NO: 1 and 3 and differ from them by addition, substitution, insertion or deletion of one or more nucleotides, but continue to code for polypeptides with the desired property profile.
  • nucleic acid sequences which comprise so-called silent mutations or which correspond to the codon usage of a specific source or host organism compared to a specific one mentioned sequence are changed, as well as naturally occurring variants, such as splice variants or allele variants thereof.
  • the subject matter is also obtainable by conservative nucleotide substitutions (ie the amino acid in question is replaced by an amino acid of the same charge, size, polarity and / or solubility).
  • the invention also relates to the molecules derived from the specifically disclosed nucleic acids by sequence polymorphisms. These genetic polymorphisms can exist between individuals within a population due to natural variation. These natural variations usually cause a 1 to 5% variance in the nucleotide sequence of a gene.
  • the invention also encompasses nucleic acid sequences which hybridize with the above-mentioned coding sequences or are complementary thereto.
  • These polynucleotides can be found when screening genomic or cDNA banks and, if appropriate, can be multiplied therefrom with suitable primers by means of PCR and then isolated, for example, with suitable probes.
  • Another possibility offers the transformation of suitable microorganisms with polynucleotides or vectors according to the invention, the multiplication of the microorganisms and thus the polynucleotides and their subsequent isolation.
  • polynucleotides according to the invention can also be synthesized chemically.
  • the property of being able to “hybridize” to polynucleotides means the ability of a poly- or oligonucleotide to bind to an almost complementary sequence under stringent conditions, while under these conditions non-specific bindings between non-complementary partners are avoided.
  • the sequences should be closed 70-100%, preferably 90-100%, are complementary
  • the property of complementary sequences to be able to bind specifically to one another is demonstrated, for example, in the Northern or Southern blot technique or in primer binding in PCR or RT-PCR Usually, oligonucleotides with a length of 30 base pairs or more are used for this.
  • “Stringent” conditions are understood to mean, for example, after the Southern or Northern blot, the DNA or RNA fragments on the membranes with a probe under specific conditions, that is, at a temperature of 60-70 ° C (38-42 ° C hybridizes with 50% hybridization solutions containing 50% formamide). Furthermore, the conditions are specific or stringent if the washing steps carried out after the hybridization for the elution of unspecifically hybridized DNA or RNA probes are also carried out specifically. Specific washing steps usually involve washing twice at 20-25 ° C for 5-10min. with 2 x SSC buffer containing 0.1% SDS (sodium dodecyl sulfate) and then washing twice with buffer of lower ionic strength (e.g.
  • antisense nucleic acids comprise a nucleotide sequence that is complementary to a coding "sense" nucleic acid.
  • the antisense nucleic acid can be complementary to the entire coding strand or only to a portion thereof "In another embodiment, the antisense nucleic acid molecule is antisense to a non-coding region of the coding strand of a nucleotide sequence.
  • non-coding region relates to the sequence segments referred to as 5 'and 3' untranslated regions.
  • An antisense oligonucleotide can be, for example, about 5, 10, 15, 20, 25, 30, 35, 40, 45 or 50 nucleotides in length.
  • An antisense nucleic acid of the invention can be constructed by chemical synthesis and enzymatic ligation reactions using methods known in the art.
  • An antisense nucleic acid can be chemically synthesized using naturally occurring nucleotides or variously modified nucleotides are used which are designed in such a way that they increase the biological stability of the molecules or increase the physical stability of the duplex which has formed between the antisense and sense nucleic acids. For example, phosphorothioate derivatives and acridine substituted nucleotides can be used.
  • modified nucleotides that can be used to generate the antisense nucleic acid include 5-fluorouracil, 5-bromouracil, 5-chlorouracil, 5-ioduracil, hypoxanthine, xanthine, 4-acetylcytosine, and the like.
  • the antisense nucleic acid molecules according to the invention are usually administered to a cell or generated in situ so that they hybridize with or bind to the cellular mRNA and / or a coding DNA so that the expression of the protein, e.g. by inhibiting transcription and / or translation.
  • the terms “express” or “amplification” or “overexpression” describe the production or increase in the intracellular activity of one or more enzymes in a microorganism that are encoded by the corresponding DNA introduce an organism, replace an existing gene with another gene, increase the number of copies of the gene or genes, use a strong promoter or use a gene which codes for a corresponding enzyme with a high activity and these measures can be combined if necessary.
  • weaken and “decrease” in the context of the invention describe the weakening or reduction of the intracellular activity of one or more enzymes in a microorganism which are encoded by the corresponding DNA. This can be done, for example, by deleting a gene in an organism, replacing an existing gene with another gene, reducing the copy number of a transcript of the gene or genes, using a weak promoter or using a gene which is suitable for a corresponding enzyme with a encodes lower activity and you can combine these measures if necessary.
  • the invention also relates to expression constructs containing, under the genetic control of regulatory nucleic acid sequences, a nucleic acid sequence coding for a polypeptide according to the invention; and vectors comprising at least one of these expression constructs.
  • Such constructs according to the invention preferably comprise a promoter 5'-upstream of the respective coding sequence and a terminator sequence 3'-downstream and optionally further customary regulatory elements, in each case operatively linked to the coding sequence.
  • operative linkage is understood to mean the sequential arrangement of promoter, coding sequence, terminator and, if appropriate, further regulatory elements in such a way that each of the regulatory elements can perform its function as intended when expressing the coding sequence.
  • sequences which can be linked operatively are targeting Sequences, as well as enhancers, polyadenylation signals and the like.
  • Further regulatory elements include selectable markers, amplification signals, origins of replication and the like. Suitable regulatory sequences are described, for example, in Goeddel, Gene Expression Technology: Methods in Enzymology 185, Academic Press, San Diego, CA (1990).
  • the natural regulatory sequence can still be present before the actual structural gene. This natural regulation can possibly be switched off by genetic modification and the expression of the genes increased or decreased.
  • the gene construct can also have a simpler structure, ie no additional regulation signals are inserted in front of the structural gene and the natural promoter with its regulation is not removed. Instead, the natural Regulation sequence mutated so that regulation no longer takes place and gene expression is increased or decreased.
  • the nucleic acid sequences can be contained in one or more copies in the gene construct.
  • Examples of useful promoters are: cos, tac, trp, tet, trp-tet, Ipp, lac, Ipp-lac, laclq, T7, T5, T3, gal, trc -, ara-, SP6-, lambda-PR or in the lambda-PL promoter, which are advantageously used in gram-negative bacteria; as well as the gram-positive promoters amy and SPO2, the yeast promoters ADC1, MFalpha, AC, P-60, CYC1, GAPDH or the plant promoters CaMV / 35S, SSU, OCS, Iib4, usp, STLS1, B33, not or the ubiquitin or phaseolin promoter.
  • inducible promoters such as, for example, light-inducible and in particular temperature-inducible promoters, such as the P r P ⁇ promoter
  • inducible promoters such as, for example, light-inducible and in particular temperature-inducible promoters, such as the P r P ⁇ promoter
  • all natural promoters with their regulatory sequences can be used.
  • synthetic promoters can also be used advantageously.
  • the regulatory sequences mentioned are intended to enable the targeted expression of the nucleic acid sequences and the protein expression. Depending on the host organism, this can mean, for example, that the gene is only expressed or overexpressed after induction, or that it is expressed and / or overexpressed immediately.
  • the regulatory sequences or factors can preferably have a positive influence on the expression and thereby increase or decrease it.
  • the regulatory elements can advantageously be strengthened at the transcription level by using strong transcription signals such as promoters and / or "enhancers".
  • an increase in translation is also possible, for example, by improving the stability of the mRNA.
  • An expression cassette is produced by fusing a suitable promoter with a suitable coding nucleotide sequence and a Terminator or polyadenylation signal.
  • Common recombination and cloning techniques are used, such as those described in T. Maniatis, EF Fritsch and J. Sambrook, Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY (1989) and TJ Silhavy, ML Berman and LW Enquist, Experiments with Gene Fusions, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY (1984) and in Ausubel, FM et al., Current Protocols in Molecular Biology, Greene Publishing Assoc. and Wiley Interscience (1987).
  • the recombinant nucleic acid construct or gene construct is advantageously inserted into a host-specific vector which enables optimal expression of the genes in the host.
  • Vectors are well known to those skilled in the art and can be found, for example, in “Cloning Vectors” (Pouwels P.H. et al., Ed., Elsevier, Amsterdam-New York-Oxford, 1985).
  • vectors are also understood to mean all other vectors known to the person skilled in the art, such as phages, viruses such as SV40, CMV, baculovirus and Aden ⁇ virus, transposons, IS elements, phasmids, cosmids, and linear or circular DNA. These vectors can be replicated autonomously in the host organism or replicated chromosomally.
  • fusion expression vectors such as pGEX (Pharmacia Biotech Ine; Smith, DB and Johnson, KS (1988) Gene 67: 31-40), pMAL (New England Biolabs, Beverly, MA) and pRIT 5 (Pharmacia, Piscataway, NJ) which glutathione-S-transferase (GST), maltose E-binding protein or protein A is fused to the recombinant target protein.
  • GST glutathione-S-transferase
  • Non-fusion protein expression vectors such as pTrc (Amann et al., (1988) Gene 69: 301-315) and pET 11d (Studier et al. Gene Expression Technology: Methods in Enzymology 185, Academic Press, San Diego, California (1990) 60-89).
  • Yeast expression vector for expression in the yeast S. cerevisiae such as pYepSed (Baldari et al., (1987) Embo J. 6: 229-234), pMFa (Kurjan and Herskowitz (1982) Cell 30: 933-943), pJRY88 (Schultz et al.
  • Vectors and methods of constructing vectors suitable for use in other fungi such as filamentous fungi include those described in detail in: van den Hondel, CAMJJ & Punt, PJ (1991) "Gene transfer Systems and vector development for filamentous fungi, in: Applied Molecular Genetics of Fungi, JF Peberdy et al., ed., pp. 1-28, Cambridge University Press: Cambridge.
  • Baculovirus vectors available for expression of proteins in cultured insect cells include the pAc series (Smith et al., (1983) Mol. Cell Bio 3: 2156-2165) and the pVL- Series (Lucklow and Summers (1989) Virology 170: 31-39).
  • Plant expression vectors such as those described in detail in: Becker, D., Kemper, E., Schell, J. and Masterson, R. (1992) "New plant binary vectors with selectable markers located proximal to the left border” , Plant Mol. Biol. 20: 1195-1197; and Bevan, M.W. (1984) "Binary Agrobacterium vectors for plant transformation", Nucl. Acids Res. 12: 8711-8721.
  • Mammalian expression vectors such as pCDM8 (Seed, B. (1987) Nature 329: 840) and pMT2PC (Kaufman et al. (1987) EMBO J. 6: 187-195).
  • Recombinant microorganisms With the aid of the vectors according to the invention, recombinant microorganisms can be produced which, for example, have been transformed with at least one vector according to the invention and can be used to produce the polypeptides according to the invention.
  • the recombinant constructs according to the invention described above are advantageously introduced and expressed in a suitable host system. Common cloning and transfection methods known to the person skilled in the art, such as, for example, coprecipitation, protoplast fusion, electroporation, retroviral transfection and the like, are preferably used in order to bring the nucleic acids mentioned into expression in the respective expression system. Suitable systems are described, for example, in Current Protocols in Molecular Biology, F.
  • homologously recombined microorganisms can also be produced.
  • a vector is produced which contains at least a section of a gene or a coding sequence according to the invention, in which, if appropriate, at least one amino acid deletion, addition or substitution has been introduced in order to change the sequence according to the invention, for example to functionally disrupt it.
  • the introduced sequence can, for example, also be a homolog from a related microorganism or can be derived from a mammalian, yeast or insect source, or the vector used for homologous recombination can alternatively be designed in such a way that the endogenous gene mutates during homologous recombination or is otherwise altered, but still encodes the functional protein (for example, the upstream regulatory region can be altered in such a way that it changes the expression of the endogenous protein).
  • the altered section of the gene according to the invention is in the homologous recombination vector tion of suitable vectors for homologous recombination is described, for example, in Thomas, KR and Capecchi, MR (1987) Cell 51: 503.
  • all organisms which enable expression of the nucleic acids according to the invention, their allele variants, their functional equivalents or derivatives are suitable as host organisms.
  • Host organisms are, for example, bacteria, fungi, yeasts, plant or animal cells.
  • Preferred organisms are bacteria, such as those of the genera Escherichia, such as. B.
  • Escherichia coli Streptomyces, Bacillus or Pseudomonas, eukaryotic microorganisms such as Saccharomyces cerevisiae, Aspergillus, higher eukaryotic cells from animals or plants, for example Sf9 or CHO cells.
  • Successfully transformed organisms can be selected using marker genes, which are also contained in the vector or in the expression cassette.
  • marker genes are genes for antibiotic resistance and for enzymes which catalyze a coloring reaction which stains the transformed cell. These can then be selected using automatic cell sorting.
  • Microorganisms successfully transformed with a vector and carrying an appropriate antibiotic resistance gene e.g. G418 or hygromycin
  • an appropriate antibiotic resistance gene e.g. G418 or hygromycin
  • Marker proteins that are presented on the cell surface can be used for selection by means of affinity chromatography.
  • the combination of the host organisms and the vectors which match the organisms, such as plasmids, viruses or phages, such as, for example, plasmids with the RNA polymerase / promoter system, phages 8 or 7 or other temperate phages or transposons and / or further advantageous regulatory ones Sequences form an expression system.
  • expression system means the combination of mammalian cells, such as CHO cells, and vectors, such as pcDNA3neo vector, which are suitable for mammalian cells.
  • the gene product can also be expressed in transgenic organisms, such as transgenic animals, in particular mice, sheep or transgenic plants.
  • transgenic organisms such as transgenic animals, in particular mice, sheep or transgenic plants.
  • the invention further relates to processes for the recombinant production of a polypeptide according to the invention or functional, biologically active fragments thereof, wherein a polypeptide-producing microorganism is cultivated, where appropriate inducing the expression of the polypeptides and isolating them from the culture.
  • the polypeptides can thus also be produced on an industrial scale, if this is desired.
  • the recombinant microorganism can be cultivated and fermented by known methods. Bacteria can be propagated, for example, in TB or LB medium and at a temperature of 20 to 40 ° C and a pH of 6 to 9. Suitable cultivation conditions are described in detail, for example, in T. Maniatis, E.F. Fritsch and J. Sambrook, Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY (1989).
  • the cells are then disrupted and the product is obtained from the lysate by known protein isolation methods.
  • the cells can optionally be operated by high-frequency ultrasound, by high pressure, e.g. in a French pressure cell, by osmolysis, by the action of detergents, lytic enzymes or organic solvents, by homogenizers or by a combination of several of the processes listed.
  • Purification of the polypeptides can be achieved with known chromatographic methods, such as molecular sieve chromatography (gel filtration), such as Q-Sepharose chromatography, ion exchange chromatography and hydrophobic chromatography, and with other customary methods such as ultrafiltration, crystallization, salting out, dialysis and native gel electrophoresis.
  • chromatographic methods such as molecular sieve chromatography (gel filtration), such as Q-Sepharose chromatography, ion exchange chromatography and hydrophobic chromatography, and with other customary methods such as ultrafiltration, crystallization, salting out, dialysis and native gel electrophoresis.
  • Suitable processes are described, for example, in Cooper, FG, Biochemical Working Methods, Verlag Walter de Gruyter, Berlin, New York or in Scopes, R., Protein Purification, Springer Verlag, New York, Heidelberg, Berlin. The same applies to non-recombinantly produced polypeptides.
  • Encode fusion proteins e.g. serve easier cleaning.
  • suitable modifications are, for example, what are known as anchors
  • Tags such as the modification known as hexa-histidine anchor or epitopes which can be recognized as antigens of antibodies (described for example in
  • Carriers such as a polymer matrix, which are used, for example, in a
  • Chromatography column can be filled, or can be used on a microtiter plate or on another support.
  • these anchors can also be used to recognize the proteins.
  • customary markers such as fluorescent dyes, enzyme markers which form a detectable reaction product after reaction with a substrate, or radioactive markers, alone or in combination with the anchors, can be used to derivatize the proteins.
  • the desired product can be obtained from the microorganism or from the culture supernatant by various methods known in the art. If the desired product is not secreted by the cells, the cells can be harvested from the culture by slow centrifugation, the cells can be lysed by standard techniques such as mechanical force or ultrasound treatment. The cell debris is removed by centrifugation and the supernatant fraction containing the soluble proteins is obtained for further purification of the desired compound. Is the product of When the cells are secreted, the cells are removed from the culture by slow centrifugation and the supernatant fraction is retained for further purification.
  • the supernatant fraction from both purification processes can be subjected to chromatography with a suitable resin, with the desired molecule either being retained on the chromatography resin or passing through it with higher selectivity than the impurities. These chromatography steps can be repeated if necessary using the same or different chromatography resins.
  • the person skilled in the art is skilled in the selection of the suitable chromatography resins and their most effective application for a particular molecule to be purified.
  • the purified product can be concentrated by filtration or ultrafiltration and kept at a temperature at which the stability of the product is maximum.
  • the identity and purity of the isolated compounds can be determined by prior art techniques. These include high performance
  • cloning steps carried out in the context of the present invention e.g. Restriction cleavages, agarose gel electrophoresis, purification of DNA fragments, transfer of nucleic acids to nitrocellulose and nylon membranes, linking of DNA fragments, transformation of cells, cultivation of bacteria, multiplication of phages and sequence analysis of recombinant DNA were carried out as in Sambrook et al. (1989) op. Cit. described.
  • Example 1 Isolation of the enzymes from cultures of Trypanosoma congolense
  • the procyclic forms of Trypanosoma congolense (deposited with the Swiss Tropical Institute Basel (STIB) as strain no. 249) can be grown at 27 ° C without CO 2 in SM / SDM 79 medium, which contains 10% fetal calf serum and hemin. After three to four days, the cell number has increased from 1x10 6 to approx. 7x10 6 / ml and the culture supernatant is separated off by centrifugation, filtered and concentrated by ultrafiltration. 84% of the enzyme activity can be determined in the culture supernatant obtained in this way, while 16% of the enzyme activity can still be detected bound to the cell pellet. The concentrated culture supernatants are used directly as enzyme concentrate for the trans-sialidase reactions. The desired sialised molecules are isolated from the culture supernatant after the reaction.
  • Example 2 Purification of the enzymes To isolate pure enzymes, the concentrated culture supernatant is placed on an ion exchange column (Q Sepharose). After washing, the column is eluted with a salt gradient. TS2 elutes with a salt concentration up to 0.2M, TS1 with a salt gradient from 0.2M. After elution, the two enzymes are purified separately by means of isoelectric focusing, gel filtration (Sephades G150 SF), affinity chromatography or protein precipitation until apparent homogeneity.
  • Q Sepharose ion exchange column
  • the sialylated product is eluted with 1 N HCl (700 ⁇ l).
  • the sample is neutralized with 250-290 ⁇ l 2N NaOH and 300 ⁇ l 1M glycine / NaOH buffer pH 10.0.
  • the fluorescence of the released methylumbelliferone is measured in black 96-well plates (Microfluor, Dynex, U.S.A.) at an excitation wavelength of 365 nm and an emission wavelength of 450 nm.
  • the activity of the enzyme corresponds to the intensity of the measured fluorescence and can be read on a previously created calibration curve (method according to Engstier et al. 1992).
  • Example 4 Production of transgenic production organisms (bacteria, yeast, fungi, plants) for the enzymes
  • the DNA partial sequences of TS1 and TS2 described here for the first time enable complete DNS To create sequences of the enzymes (especially since the DNA sequences presented here do not contain any non-coding introns).
  • the corresponding standard techniques are e.g. B. the “polymerase chain reaction” technique (PCR technique), “Southern blott” via genomic DNA or cDNA and mRNA techniques, which can be carried out with the aid of commercially available kits, for example from Invitrogen or Clontech , The techniques are known to the person skilled in the art and are described, inter alia, in: Ausubel et al: Current Protocols in Molecular Biology, Edition 1989 and 2001.
  • the complete DNA of the respective enzymes or functional partial sequences thereof are converted into the by means of standard transformation techniques (Ausubel et al.) desired production organisms introduced.
  • the transgenic organisms produce TS1 and TS2 and can be isolated from the transgenic organisms and / or their culture supernatants.
  • Prokaryotic bacteria, eukaryotic microorganisms, yeasts and other fungi, eukaryotic cell cultures, algae, plants, seeds, animals, parts of animals, tissues, hybridomas, transgenic organisms and genetic, gene therapeutic and transgenic come as recipient organisms of the DNA that codes TS1 or TS2 Recombinants and derived organisms, organs, tissues and cells are used.
  • the enzymes claimed here can be isolated from the corresponding whole or parts of transgenic organisms, from their culture supernatants, from organs, tissues, cells, biological fluids, exudates, eggs, blood, lymph, milk, plants, algae and seeds and from parts thereof ,
  • GMP glycomacropeptide
  • Tris buffer pH 7.0 e.g. from Merk, Darmstadt
  • the solution is mixed with 1 liter of the trans-sialidase-containing culture supernatant from Trypanosoma congolense and incubated at 37 ° C. for 3 hours. After this period, the trans-sialidase transferred sialic acids from the GMP to the galactooligosaccharides.
  • the specialized products can with the help usual chromatographic methods (Ausubel et al.) or filter techniques can be separated and cleaned and are available in pure form for product formulations.
  • Glycomacropeptide is a waste product from the production of cheese from cow's milk. After the casein for cheese preparation has been precipitated, it can be isolated from the remaining whey using filter techniques.
  • Galactooligosaccharides are made by reacting lactose using the commercially available enzyme beta-galactosidase. In this reaction, beta-galactosidase splits the lactose into its monomeric sugars. On the other hand, this reaction also produces longer-chain galactooligosaccharides in a side reaction, which can be separated off and are then available as acceptors for the trans-sialidase reaction.
  • the two isolated enzymes can be used, for example, for the sialylation of polymers containing beta-galactose (such as gum arabic, etc.) and in particular for polylactosamines and galactans and for galactooligosaccharides (GOS), in particular for beta-galacto-oligosaccharides, such as, for. B. Vivinal GOS from Borculo Domo Ingredients (BDI) and Oligomate 55 from Yakult.
  • beta-galactose such as gum arabic, etc.
  • GOS galactooligosaccharides
  • Siglecs a family of sialic-acid binding lectins. Glycobiology 8, v.
  • the developmentally regulated trans-sialidase from Trypanosoma brucei sialylates the procyclic acidic repetitive protein. Moles of Biochem Parasitol; 61: 1-13.
  • the receptor-destroying enzyme of influenza C virus is neuraminate-O-acetylesterase. EMBO J. 4, 1503-1506.
  • Influenza virus hemagglutinins differentiate between receptor determinants bearing N-acetyl-, N-glycolyl-, and N, O- diacetyl-neuraminic acids.
  • Keim, S. and Schauer, R. (1997). Sialic acids in molecular and cellular interactions. Int. Rev. Cytol. 175: 137-240. Keim, S., Schauer, R. and Crocker, P.R. (1996). The Sialoadhesins - a family of sialic acid-dependent cellular recognition molecules within the immunoglobulin superfamily. Glycoconj. J. 13: 913-926.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Transplantation (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • General Preparation And Processing Of Foods (AREA)

Abstract

L'invention se rapporte à de nouvelles enzymes qui transfèrent des acides sialiques, d'une molécule donneuse sur une molécule réceptrice (trans-sialidases). Ces enzymes sont isolées dans le protozoaire Trypanosoma congolense. Cette invention concerne en outre : des équivalents fonctionnels de ces enzymes ; les séquences d'acides nucléiques et les séquences d'acides aminés codant ces enzymes et leurs équivalents fonctionnels ; des constructions d'expression et des vecteurs contenant ces séquences ; des micro-organimes recombinés comportant une séquence d'acides nucléiques de codage selon l'invention ; un procédé de production des enzymes selon l'invention, par recombinaison ; un procédé pour isoler les enzymes selon l'invention dans le protozoaire Trypanosoma congolense ; un procédé de sialylation enzymatique de molécules réceptrices, au moyen des enzymes selon l'invention ; des effecteurs des trans-sialidases selon l'invention ; l'utilisation des séquences d'acides nucléiques, séquences d'acides aminés, enzymes, effecteurs ou produits de sialylation selon l'invention pour produire des vaccins, médicaments, produits alimentaires ou compléments alimentaires ; ainsi que les agents produits selon l'invention.
EP03785794A 2002-12-13 2003-12-11 Trans-sialidases issues de trypanosoma congolense Withdrawn EP1570054A2 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE10258400A DE10258400A1 (de) 2002-12-13 2002-12-13 Trans-Sialidasen aus Trypanosoma congolense
DE10258400 2002-12-13
PCT/EP2003/014079 WO2004055176A2 (fr) 2002-12-13 2003-12-11 Trans-sialidases issues de trypanosoma congolense

Publications (1)

Publication Number Publication Date
EP1570054A2 true EP1570054A2 (fr) 2005-09-07

Family

ID=32336317

Family Applications (1)

Application Number Title Priority Date Filing Date
EP03785794A Withdrawn EP1570054A2 (fr) 2002-12-13 2003-12-11 Trans-sialidases issues de trypanosoma congolense

Country Status (9)

Country Link
US (1) US7655784B2 (fr)
EP (1) EP1570054A2 (fr)
JP (1) JP2006509515A (fr)
CN (1) CN1726279A (fr)
AU (1) AU2003294833A1 (fr)
CA (1) CA2509070A1 (fr)
DE (1) DE10258400A1 (fr)
RU (1) RU2393222C2 (fr)
WO (1) WO2004055176A2 (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7807174B2 (en) * 2002-11-22 2010-10-05 Nexbio, Inc. Class of therapeutic protein based molecules
WO2008055316A1 (fr) * 2006-11-10 2008-05-15 Marshall Barry J Procédés et dispositifs permettant l'administration de peptides dans la muqueuse gastrique
FR2952382B1 (fr) * 2009-11-10 2011-11-25 Univ Victor Segalen Bordeaux 2 Vaccins et diagnostics contre les trypanosomoses animales africaines
FR2952649B1 (fr) 2009-11-13 2012-05-04 Univ Victor Segalen Bordeaux 2 Applications therapeutiques et diagnostiques contre les trypanosomoses animales africaines
KR101221666B1 (ko) 2010-06-18 2013-01-14 한국생명공학연구원 효모 표면 발현된 코리네박테리움 디프테리아 유래 트랜스-시알리다아제 및 이를 이용한 시알산 전구체 제조방법
NL2007931C2 (en) * 2011-12-07 2013-06-10 Friesland Brands Bv Methods for providing sialylated oligosaccharides and products obtainable thereby.
EP2864492A4 (fr) * 2012-06-22 2016-06-15 Glycom As Galacto-oligosaccharides modifiés
WO2014167112A1 (fr) * 2013-04-12 2014-10-16 Danmarks Tekniske Universitet Sialidase mutante ayant une activité de trans-sialidase destinée à être utilisée en production de glycanes sialylés
CA2908407C (fr) * 2013-05-29 2022-06-14 F. Hoffmann-La Roche Ag Regulation quantitative de la sialylation
CN114395545B (zh) * 2021-04-22 2023-05-12 成都欧林生物科技股份有限公司 一种用于抵御幽门螺杆菌在胃内定植的唾液酸酶

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5949226A (en) * 1995-04-10 1999-09-07 Kabushiki Kaisha Toyoda Jidoshokki Seisakush DC/DC converter with reduced power consumpton and improved efficiency

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO2004055176A2 *

Also Published As

Publication number Publication date
RU2005122020A (ru) 2006-01-27
AU2003294833A1 (en) 2004-07-09
CA2509070A1 (fr) 2004-07-01
RU2393222C2 (ru) 2010-06-27
CN1726279A (zh) 2006-01-25
DE10258400A1 (de) 2004-06-24
US20070004656A1 (en) 2007-01-04
JP2006509515A (ja) 2006-03-23
WO2004055176A3 (fr) 2005-05-26
WO2004055176A2 (fr) 2004-07-01
US7655784B2 (en) 2010-02-02
AU2003294833A8 (en) 2004-07-09

Similar Documents

Publication Publication Date Title
Traving et al. Structure, function and metabolism of sialic acids
Varki et al. Sialic acids
Funderburgh et al. Mimecan, the 25-kDa corneal keratan sulfate proteoglycan, is a product of the gene producing osteoglycin
AU2014320757C1 (en) Production of oligosaccharides
DE69928121T2 (de) Verwendungen von sulfatierten fuko-oligosacchariden zum pflanzenschutz
EP2437769B1 (fr) Préparation de peptides de manière recombinée
JP5597890B2 (ja) 新規のプレバイオティクス
WO2004055176A2 (fr) Trans-sialidases issues de trypanosoma congolense
Zhu et al. Tissue-specific expression of phospholipase C encoded by the norpA gene of Drosophila melanogaster
EP0786004B1 (fr) Clonage, expression et caracterisation d'une nouvelle forme de phosphatidylinositol-3-kinase
Haksar et al. Neuraminidase treatment of adrenal cells increases their response to cholera enterotoxin
Iguchi et al. Isolation and characterization of a novel protein toxin from fire coral
DE2930604A1 (de) Doppelstrangige ribonucleinsaeure, verfahren zu ihrer herstellung und diese enthaltende interferon-induktoren
Fukano et al. Preparation of GM1 ganglioside with sialidase-producing marine bacteria as a microbial biocatalyst
EP1059353B1 (fr) Nouvelle proteine calpaine et adn codant ladite proteine
Mulligan-Tuttle et al. Expression of the small heat shock protein gene, hsp30, in Rana catesbeiana fibroblasts
Bora et al. Cloning and characterization of a putative mouse acetyl-CoA transporter cDNA
DE60317481T2 (de) Produktion einer ugppase
Modi et al. Functional relationship between ammonia and gangliosides in brain
EP1419254A2 (fr) Produits geniques de ashbya gossypii associes au transport transmembranique
DE4445562C1 (de) Klonierung, Expression und Charakterisierung einer neuen Form der Phosphatidylinositol-3-Kinase
DE19949595A1 (de) CTAGE-Genfamilie
US20050053932A1 (en) Novel stress-associated genetic products from ashbya gossypii
EP1414962A1 (fr) Nouveaux produits genetiques issus de ashbya gossypii associes aux mecanismes de la transduction de signal, notamment a l'amelioration de la production de vitamine b2
EP1423420A2 (fr) Nouveaux produits geniques issus de ashbya gossypii associes aux mecanismes de la transcription, de la maturation de l'arn et/ou de la traduction

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20050627

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL LT LV MK

DAX Request for extension of the european patent (deleted)
17Q First examination report despatched

Effective date: 20061116

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20130702